These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25487528)

  • 21. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria.
    Li X; Lv R; He Q; Li H; Du X; Lin W; Li Q; He X; Wang S; Chen J
    J Nephrol; 2008; 21(4):584-91. PubMed ID: 18651550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance immunosuppression in myasthenia gravis.
    Gotterer L; Li Y
    J Neurol Sci; 2016 Oct; 369():294-302. PubMed ID: 27653912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic Thymoma-Associated Myasthenia Gravis: Favorable Response to Steroid Pulse Therapy Plus Immunosuppressive Agent.
    Qi G; Liu P; Dong H; Gu S; Yang H; Xue Y
    Med Sci Monit; 2017 Mar; 23():1217-1223. PubMed ID: 28278141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
    Harper L; Morgan MD; Walsh M; Hoglund P; Westman K; Flossmann O; Tesar V; Vanhille P; de Groot K; Luqmani R; Flores-Suarez LF; Watts R; Pusey C; Bruchfeld A; Rasmussen N; Blockmans D; Savage CO; Jayne D;
    Ann Rheum Dis; 2012 Jun; 71(6):955-60. PubMed ID: 22128076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment of refractory generalized myasthenia gravis with rituximab.
    Lebrun C; Bourg V; Tieulie N; Thomas P
    Eur J Neurol; 2009 Feb; 16(2):246-50. PubMed ID: 19146644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    De Groot K; Rasmussen N; Bacon PA; Tervaert JW; Feighery C; Gregorini G; Gross WL; Luqmani R; Jayne DR
    Arthritis Rheum; 2005 Aug; 52(8):2461-9. PubMed ID: 16052573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation.
    Hasselblatt P; Drognitz K; Potthoff K; Bertz H; Kruis W; Schmidt C; Stallmach A; Schmitt-Graeff A; Finke J; Kreisel W
    Aliment Pharmacol Ther; 2012 Oct; 36(8):725-35. PubMed ID: 22937722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of refractory giant cell arteritis with cyclophosphamide:a retrospective analysis of 35 patients from three centres.
    Loock J; Henes J; Kötter I; Witte T; Lamprecht P; Schirmer M; Gross WL
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S70-6. PubMed ID: 22640650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study.
    Singh N; Goyal V
    J Neurol; 2019 Jul; 266(7):1596-1600. PubMed ID: 30919039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial.
    Seror R; Pagnoux C; Ruivard M; Landru I; Wahl D; Rivière S; Aussant S; Mahr A; Cohen P; Mouthon L; Guillevin L;
    Ann Rheum Dis; 2010 Dec; 69(12):2125-30. PubMed ID: 20643762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myelopathies secondary to Sjögren's syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids.
    de Seze J; Delalande S; Fauchais AL; Hachulla E; Stojkovic T; Ferriby D; Hatron PY; Vermersch P
    J Rheumatol; 2006 Apr; 33(4):709-11. PubMed ID: 16583474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study.
    Bae S; Charles-Schoeman C
    Clin Rheumatol; 2018 Aug; 37(8):2113-2123. PubMed ID: 29971584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease.
    Suelves AM; Arcinue CA; González-Martín JM; Kruh JN; Foster CS
    Ophthalmology; 2013 Jun; 120(6):1201-9. PubMed ID: 23601800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The difference between lupus nephritis class IV-G and IV-S in Koreans: focus on the response to cyclophosphamide induction treatment.
    Kim YG; Kim HW; Cho YM; Oh JS; Nah SS; Lee CK; Yoo B
    Rheumatology (Oxford); 2008 Mar; 47(3):311-4. PubMed ID: 18204087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome.
    Li X; Li H; Chen J; He Q; Lv R; Lin W; Li Q; He X; Qu L; Suya W
    Nephrol Dial Transplant; 2008 Jun; 23(6):1919-25. PubMed ID: 17911091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis.
    Drachman DB; Adams RN; Hu R; Jones RJ; Brodsky RA
    Ann N Y Acad Sci; 2008; 1132():305-14. PubMed ID: 18567882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged treatment with low-dose intravenous pulse cyclophosphamide may reduce rate of relapse in ANCA-associated vasculitis.
    Dhaygude A; Griffith M; Cairns T; McLean A; Palmer A; Taube D
    Nephron Clin Pract; 2004; 97(4):c154-9. PubMed ID: 15331939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis.
    Kerkeni S; Marotte H; Miossec P
    Muscle Nerve; 2008 Oct; 38(4):1343-5. PubMed ID: 18816604
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.